{
  "name": "Radioiodine-Refractory Differentiated Thyroid Carcinoma",
  "specialty": "nuclear_medicine",
  "chief_complaint": "Persistent neck swelling and fatigue despite previous radioactive iodine treatment",
  "symptoms": [
    "Progressive neck mass",
    "Hoarseness",
    "Dysphagia",
    "Unexplained weight loss",
    "Bone pain"
  ],
  "physical_findings": [
    "Firm, fixed thyroid nodule",
    "Cervical lymphadenopathy",
    "Vocal cord paralysis on laryngoscopy"
  ],
  "lab_results": {
    "Thyroglobulin": ">1000 ng/mL (rising)",
    "TSH": "Suppressed",
    "FT4": "Normal",
    "FT3": "Elevated"
  },
  "treatment": [
    "Multikinase inhibitors (lenvatinib or sorafenib)",
    "External beam radiation for symptomatic metastases",
    "Palliative care coordination",
    "Clinical trial enrollment"
  ],
  "prognosis": "Guarded with median survival of 3-5 years after diagnosis of refractoriness",
  "description": "A challenging subset of differentiated thyroid cancer that loses the ability to concentrate radioactive iodine despite TSH stimulation, often with aggressive metastatic behavior. Typically develops after multiple I-131 treatments with progressive thyroglobulin elevation and imaging evidence of disease progression.",
  "risk_factors": [
    "Prior high-dose radioactive iodine exposure",
    "Tall-cell variant histology",
    "BRAF V600E mutation",
    "Extrathyroidal extension at initial surgery"
  ],
  "patient_behavior": {
    "anxiety_level": "high",
    "cooperation": "good",
    "pain_level": "6"
  },
  "case_id": "hard_nuclear_medicine_001",
  "difficulty": "hard",
  "multiple_choice": [
    "Anaplastic Thyroid Carcinoma",
    "Radioiodine-Refractory Differentiated Thyroid Carcinoma",
    "Medullary Thyroid Carcinoma",
    "Thyroid Lymphoma"
  ]
}